Skip to main content
. 2022 Nov 10;9:1054431. doi: 10.3389/fnut.2022.1054431

Figure 3.

Figure 3

MBP immunostaining of neural primary cells after treatment with 2′-FL and OPN and DHA for 30 days. (A), control group; (B), positive drug; (C), 2′-FL(H); (D), OPN(H); (E), DHA(H); (F), 2′-FL(L)+OPN(L); (G), 2′-FL(L)+OPN(H); (H), 2'-FL(M)+OPN(M); (I), 2′-FL(H)+OPN(L); (J), 2′-FL(H)+OPN(H); (K), 2′-FL(LM)+OPN(LM); (L), 2′-FL(MH) +OPN(MH); (M), 2′-FL(L)+OPN(L)+DHA(L); (N), 2′-FL(L)+OPN(M)+DHA(M); (O), 2′-FL(H)+OPN(H)+DHA(H); (P), 2′-FL(LM)+OPN(LM)+DHA(LM); (Q), 2′-FL(MH)+OPN(MH)+DHA(MH). Scale bar: 50 μm.